questionsmedicales.fr
Maladies de la peau et du tissu conjonctif
Maladies de la peau
Sclérodermie systémique
Sclérodermie diffuse
Sclérodermie diffuse : Questions médicales fréquentes
Termes MeSH sélectionnés :
Medication Reconciliation
Diagnostic
5
Sclérodermie
Diagnostic médical
Signes cliniques
Sclérodermie
Radiographie
Sclérodermie
Symptômes
5
Symptômes respiratoires
Sclérodermie
Atteinte digestive
Sclérodermie
Troubles vasculaires
Sclérodermie
Prévention
5
Facteurs de risque
Sclérodermie
Exposition au froid
Sclérodermie
Traitements
5
Corticostéroïdes
Sclérodermie
Kinésithérapie
Sclérodermie
Traitements expérimentaux
Sclérodermie
Symptômes cutanés
Sclérodermie
Complications
5
Complications
Sclérodermie
Atteintes cardiaques
Sclérodermie
Atteintes rénales
Sclérodermie
Complications digestives
Sclérodermie
Facteurs de risque
5
Facteurs de risque
Sclérodermie
Facteurs environnementaux
Sclérodermie
Maladies auto-immunes
Sclérodermie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sclérodermie diffuse : Questions médicales les plus fréquentes",
"headline": "Sclérodermie diffuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sclérodermie diffuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-29",
"dateModified": "2025-02-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sclérodermie systémique",
"url": "https://questionsmedicales.fr/mesh/D012595",
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie systémique",
"code": {
"@type": "MedicalCode",
"code": "D012595",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C17.800.784"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse",
"alternateName": "Scleroderma, Diffuse",
"code": {
"@type": "MedicalCode",
"code": "D045743",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Dinesh Khanna",
"url": "https://questionsmedicales.fr/author/Dinesh%20Khanna",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA."
}
},
{
"@type": "Person",
"name": "Christopher P Denton",
"url": "https://questionsmedicales.fr/author/Christopher%20P%20Denton",
"affiliation": {
"@type": "Organization",
"name": "UCL Division of Medicine, Royal Free Campus, London, UK."
}
},
{
"@type": "Person",
"name": "Ami A Shah",
"url": "https://questionsmedicales.fr/author/Ami%20A%20Shah",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA. Electronic address: Ami.Shah@jhmi.edu."
}
},
{
"@type": "Person",
"name": "Susanna Proudman",
"url": "https://questionsmedicales.fr/author/Susanna%20Proudman",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "[Medication reconciliation: Interests and limits].",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36841717",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.revmed.2023.02.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Medication reconciliation, an innovative partnership].",
"datePublished": "2022-05-26",
"url": "https://questionsmedicales.fr/article/36127018",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.soin.2022.05.027"
}
},
{
"@type": "ScholarlyArticle",
"name": "Electronic Medication Reconciliation Tools Aimed at Healthcare Professionals to Support Medication Reconciliation: a Systematic Review.",
"datePublished": "2023-12-06",
"url": "https://questionsmedicales.fr/article/38055124",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10916-023-02008-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Medication reconciliation in pediatrics: a validation of instruments to prevent medication errors.",
"datePublished": "2023-03-06",
"url": "https://questionsmedicales.fr/article/36888795",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/0034-7167-2021-0755"
}
},
{
"@type": "ScholarlyArticle",
"name": "Incidence and Severity of Medication Reconciliation Discrepancies in Trauma Patients.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36853593",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/00031348231161686"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de la peau et du tissu conjonctif",
"item": "https://questionsmedicales.fr/mesh/D017437"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de la peau",
"item": "https://questionsmedicales.fr/mesh/D012871"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sclérodermie systémique",
"item": "https://questionsmedicales.fr/mesh/D012595"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sclérodermie diffuse",
"item": "https://questionsmedicales.fr/mesh/D045743"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sclérodermie diffuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sclérodermie diffuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sclérodermie diffuse",
"description": "Comment diagnostiquer la sclérodermie diffuse ?\nQuels tests sanguins sont utilisés ?\nLes biopsies cutanées sont-elles nécessaires ?\nQuels signes cliniques sont observés ?\nLa radiographie est-elle utile dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Reconciliation#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sclérodermie diffuse",
"description": "Quels sont les symptômes principaux ?\nLa fatigue est-elle un symptôme courant ?\nY a-t-il des symptômes respiratoires ?\nComment se manifeste l'atteinte digestive ?\nLes troubles vasculaires sont-ils fréquents ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Reconciliation#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sclérodermie diffuse",
"description": "Peut-on prévenir la sclérodermie diffuse ?\nQuels facteurs de risque sont identifiés ?\nLe tabagisme influence-t-il la maladie ?\nL'exposition au froid est-elle un risque ?\nLes infections peuvent-elles aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Reconciliation#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sclérodermie diffuse",
"description": "Quels traitements sont disponibles ?\nLes corticostéroïdes sont-ils efficaces ?\nQuelles thérapies physiques sont recommandées ?\nY a-t-il des traitements expérimentaux ?\nComment gérer les symptômes cutanés ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Reconciliation#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sclérodermie diffuse",
"description": "Quelles sont les complications possibles ?\nLa sclérodermie peut-elle affecter le cœur ?\nY a-t-il un risque d'infections ?\nComment la sclérodermie affecte-t-elle les reins ?\nLes complications digestives sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Reconciliation#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sclérodermie diffuse",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils significatifs ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nLe stress peut-il aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Reconciliation#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la sclérodermie diffuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, les antécédents médicaux et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la recherche d'anticorps spécifiques comme les anticorps anti-Scl-70."
}
},
{
"@type": "Question",
"name": "Les biopsies cutanées sont-elles nécessaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être réalisées pour évaluer l'atteinte tissulaire et confirmer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent un durcissement de la peau, des œdèmes et des troubles vasculaires."
}
},
{
"@type": "Question",
"name": "La radiographie est-elle utile dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aider à évaluer les atteintes pulmonaires ou digestives associées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent un durcissement de la peau, des douleurs articulaires et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue est fréquente et peut être liée à l'inflammation et à l'atteinte organique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes respiratoires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des difficultés respiratoires peuvent survenir en raison de l'atteinte pulmonaire."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'atteinte digestive ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se traduire par des reflux, des troubles de la déglutition et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Les troubles vasculaires sont-ils fréquents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des phénomènes de Raynaud et des ulcères digitaux peuvent se produire."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la sclérodermie diffuse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention connue, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont identifiés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des expositions environnementales et le sexe féminin."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la maladie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut aggraver les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "L'exposition au froid est-elle un risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition au froid peut déclencher des symptômes vasculaires comme le phénomène de Raynaud."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la maladie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent exacerber les symptômes et compliquer la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunosuppresseurs, des anti-inflammatoires et des thérapies symptomatiques."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire l'inflammation, mais leur utilisation doit être prudente en raison des effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles thérapies physiques sont recommandées ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La kinésithérapie peut aider à maintenir la mobilité et à réduire la douleur articulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les inhibiteurs de la tyrosine kinase sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes cutanés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crèmes hydratantes et des traitements topiques peuvent aider à soulager les symptômes cutanés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des atteintes pulmonaires, cardiaques et rénales, ainsi que des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La sclérodermie peut-elle affecter le cœur ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des arythmies, une hypertension pulmonaire et une insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque d'infections ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent être plus susceptibles aux infections en raison d'une immunité altérée."
}
},
{
"@type": "Question",
"name": "Comment la sclérodermie affecte-t-elle les reins ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer une hypertension rénale et une insuffisance rénale, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Les complications digestives sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des reflux, des troubles de la motilité et des malabsorption."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le sexe féminin et certaines expositions environnementales sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la sclérodermie diffuse survient généralement entre 30 et 50 ans, mais peut toucher d'autres âges."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils significatifs ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des solvants organiques et à la silice peut augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes ayant d'autres maladies auto-immunes peuvent avoir un risque accru."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver la maladie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut exacerber les symptômes, bien que son rôle exact dans la sclérodermie ne soit pas clair."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 23/02/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
4 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Publications dans "Sclérodermie diffuse" :
4 publications dans cette catégorie
Affiliations :
UCL Division of Medicine, Royal Free Campus, London, UK.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA. Electronic address: Ami.Shah@jhmi.edu.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Department of Woman's and Child's Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy. francescozulian58@gmail.com.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Georgetown University Medical Center, Washington (DC), USA.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Lady Davis Institute of the Jewish General Hospital, 4333 Côte-Sainte-Catherine Road,, Montréal, Québec, H3T 1E4, Canada. brett.thombs@mcgill.ca.
Department of Psychology, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Psychiatry, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Medicine, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Educational and Counselling Psychology, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Biomedical Ethics Unit, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
University of Pittsburgh, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Rheumatology, Justus-Liebig University Giessen, Giessen, Germany.
Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Rheumatology Unit, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Woman's and Child's Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy.
Publications dans "Sclérodermie diffuse" :
Admission to hospital is a critical transition point for the continuity of care in medication management. Medication reconciliation can identify and resolve errors due to inaccurate medication histori...
An innovative partnership between advanced practice nurses (APN) in psychiatry and mental health, the pharmacy department of a public health institution and the various health care professionals in th...
The development of health information technology available and accessible to professionals is increasing in the last few years. However, a low number of electronic health tools included some kind of i...
to develop and validate the content of two instruments for promoting medication reconciliation for the transition of care of hospitalized children....
methodological study, conducted in five stages: scope review for conceptual structure; elaboration of the initial version; content validation with five specialists using the Delphi technique; reassess...
three rounds of evaluation were carried out to reach the validity index of the proposed contents, whereas a new analysis of 50% of the 20 items of the instrument aimed at families, and 28.5% of the 21...
the proposed instruments were validated. It is now possible to proceed with practical implementation studies to identify their influence on safety during medication reconciliation at transition of car...
Trauma patients are especially vulnerable to inadvertent medication reconciliation discrepancies. We conducted a prospective study to evaluate the USA Health University Hospital's incidence and type o...
Entrustable professional activities (EPAs) are observable process descriptions of clinical work units. EPAs support learners and tutors in assessment within healthcare settings. For use amongst our ph...
The development of the clinical pharmacy EPA followed a set pathway. A rapid literature review informed the first draft, an interprofessional consensus group consisting of pharmacists, nurses, and med...
We designed, refined and validated an EPA regarding medication reconciliation for assessment of pharmacy students and trainees within the pharmacy department at LMU University Hospital in Munich. Alon...
We developed the first clinical pharmacy EPA for use in a German context. Medication reconciliation is a suitable EPA candidate as it describes a clinical activity performed by pharmacists in many cli...
Medication reconciliation, a technique that assists in aligning a care team's understanding of an individual's true medication regimen, is vital to optimize medication use and prevent medication error...
Academic researchers, older adults, and community- and health system-based healthcare professionals engaged in a participatory process to better understand medication reconciliation barriers and co-de...
Sparks Innovation Studios identified a lack of ownership, fragmented healthcare systems, and time constraints as the leading barriers to medication reconciliation. The Community Consultation Studio re...
Engaging community representatives with academic partners in the research process enhanced understanding of community priorities and provided a practical roadmap for innovations that have the potentia...
In orthopedic surgery, the well-known iatrogenic risk of oral anticoagulants is particularly increased due to surgical management (suspension and resumption of treatment). In order to prevent avoidabl...
The second Multicenter Medication Reconciliation Quality Improvement Study demonstrated a marked reduction in medication discrepancies per patient. The aim of the current analysis was to determine the...
This study was conducted at 17 North American Hospitals, the study period was 18 months per site, and sites typically adopted interventions after 2-5 months of preintervention data collection. We cond...
Among 4947 patients, patient exposure to seven of the eight system-level component categories was associated with modest but significant reductions in discrepancy rates (adjusted rate ratios (ARR) 0.7...
Patient-level interventions most associated with reductions in discrepancies were receipt of a BPMH of admitted patients in the ED and admission and discharge medication reconciliation by a trained cl...
To collect the community pharmacists' perception on their role in the medication reconciliation's process....
We did an observational transverse study thanks to a survey of community pharmacists working in France, conducted in 2020. A digital questionnaire was submitted to Parisian community pharmacists befor...
We collected the perception of 135 community pharmacists, the majority was women (80%), relatively young (69.6% of 40 years old or less). They were 63.7% to claim knowing the medication reconciliation...
Although the community pharmacists expressed interest for the medication reconciliation process and willingness to get involved, their role remained limited. Therefore, this process needs an improveme...